Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can smarter remote monitoring keep heart failure patients out of the hospital?

NCT ID NCT03012490

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 652 heart failure patients who had a special heart device (CRT). One group received standard remote monitoring, while the other got more detailed monitoring that also tracked heart rhythm issues and symptoms. The goal was to see if the extra monitoring could reduce deaths or hospital visits for worsening heart failure over 27 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remote monitoring (comprehensive vs standard)
What this could lead to
If successful, this could show that more detailed remote monitoring helps heart failure patients live longer and avoid hospital stays.
What could go wrong
This trial is already completed, so results are known. The approach may not significantly improve outcomes over standard care, and benefits may vary by patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

652 people

The number who actually took part.

Started

Feb 2017

Finished

Jun 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient more than 18 years old, newly implanted, in accordance to the latest European guidelines, with a CRT-P or CRT-D device (upgrading is tolerated but no device replacement), with Home-Monitoring® activated * Patient willing and able to comply with the protocol and who has provided written informed consent Exclusion Criteria: * Lead model under advisory * Non-functional lead except particular case of non-functional or deactivated right atrial lead due to atrial fibrillation * Known drug or alcohol abuse * Pregnant woman or woman who plan to become pregnant during the trial (the data will be collected by querying the patient without a pregnancy test is required) * Participation (ongoing or planned during the trial) in another interventional clinical study, and/or another remote monitoring and/or follow-up concept, unless authorized by the Executive Committee * Participation (ongoing or planned during the trial) in an investigational HF program (e.g. PRADO, PIMPS, OSICAT, CARDIAUVERGNE) * Estimated life-expectancy, regardless of the cardiovascular condition, \<1year * Patient under- or planned for - ventricular assistance * Patient not living in Metropolitan France and/or not geographically stable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac resynchronization therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac resynchronization therapy Heart failure

Contacts and locations

Locations

  • Institut coeur poumon, CHRU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.